SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

被引：19

作者：

Hope, Thomas A. ^{[1
]}

Antonarakis, Emmanuel S. ^{[2
]}

Bodei, Lisa ^{[3
]}

Calais, Jeremie ^{[4
]}

Iravani, Amir ^{[5
]}

Jacene, Heather ^{[6
,7
]}

Koo, Phillip J. ^{[8
]}

Morgans, Alicia K. ^{[9
]}

Osborne, Joseph R. ^{[10
]}

Tagawa, Scott T. ^{[11
]}

Taplin, Mary-Ellen ^{[9
]}

Sartor, Oliver ^{[12
]}

Morris, Michael J. ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[2] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA

[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA

[4] UCLA, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA USA

[5] Univ Washington, Dept Radiol, Seattle, WA 98195 USA

[6] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA

[7] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA

[8] Banner MD Anderson Canc Ctr, Phoenix, AZ USA

[9] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[10] Weill Cornell Med, Mol Imaging & Therapeut, Dept Radiol, New York, NY USA

[11] Weill Cornell Med Coll, Dept Med, New York, NY USA

[12] Mayo Clin, Rochester, MN USA

[13] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 09期

关键词：

RESISTANT PROSTATE-CANCER; SURVIVAL; CABAZITAXEL; SAFETY;

D O I：

10.2967/jnumed.123.265952

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Prostate-specific membrane antigen (PSMA) is a transmem-brane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan [Pluvicto; Novartis]) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) after progressing on taxane-based chemotherapy and at least 1 line of androgen recep-tor pathway inhibitors (ARPIs). This document aims to provide standardized guidance through expert consensus for the selection and management of patients being treated with 177Lu-PSMA RLT.

引用

页码：1417 / 1423

页数：7

共 30 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2] Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade [J].

Abida, Wassim ;

Cheng, Michael L. ;

Armenia, Joshua ;

Middha, Sumit ;

Autio, Karen A. ;

Vargas, Hebert Alberto ;

Rathkopf, Dana ;

Morris, Michael J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Carbone, Emily ;

Barnett, Ethan S. ;

Hullings, Melanie ;

Hechtman, Jaclyn F. ;

Zehir, Ahmet ;

Shia, Jinru ;

Jonsson, Philip ;

Stadler, Zsofia K. ;

Srinivasan, Preethi ;

Laudone, Vincent P. ;

Reuter, Victor ;

Wolchok, Jedd D. ;

Socci, Nicholas D. ;

Taylor, Barry S. ;

Berger, Michael F. ;

Kantoff, Philip W. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Solit, David B. ;

Gopalan, Anuradha ;

Scher, Howard I. .

JAMA ONCOLOGY, 2019, 5 (04) :471-478

[3] Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride [J].

Ahmadzadehfar, Hojjat ;

Zimbelmann, Stefanie ;

Yordanova, Anna ;

Fimmers, Rolf ;

Kuerpig, Stefan ;

Eppard, Elisabeth ;

Gaertner, Florian C. ;

Wei, Xiao ;

Hauser, Stefan ;

Essler, Markus .

ONCOTARGET, 2017, 8 (33) :55567-55574

[4] Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial [J].

Bahl, A. ;

Oudard, S. ;

Tombal, B. ;

Ozguroglu, M. ;

Hansen, S. ;

Kocak, I. ;

Gravis, G. ;

Devin, J. ;

Shen, L. ;

de Bono, J. S. ;

Sartor, A. O. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2402-2408

[5] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[6] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial [J].

Buteau, James P. ;

Martin, Andrew J. ;

Emmett, Louise ;

Iravani, Amir ;

Sandhu, Shahneen ;

Joshua, Anthony M. ;

Francis, Roslyn J. ;

Zhang, Alison Y. ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Azad, Arun A. ;

McJannett, Margaret M. ;

Stockler, Martin R. ;

Williams, Scott G. ;

Davis, Ian ;

Hofman, Michael S. .

LANCET ONCOLOGY, 2022, 23 (11) :1389-1397

[7] PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). [J].

Buteau, James Patrick ;

Martin, Andrew James ;

Emmett, Louise ;

Iravani, Amir ;

Sandhu, Shahneen Kaur ;

Joshua, Anthony M. ;

Zhang, Alison Yan ;

Francis, Roslyn J. ;

Scott, Andrew Mark ;

Azad, Arun ;

McJannett, Margaret Mary ;

Stockler, Martin R. ;

Williams, Scott ;

Davis, Ian D. ;

Hofman, Michael S. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

[8] Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort [J].

Calais, Jeremie ;

Gafita, Andrei ;

Eiber, Matthias ;

Armstrong, Wesley R. ;

Gartmann, Jeannine ;

Thin, Pan ;

Nguyen, Kathleen ;

Lok, Vincent ;

Gosa, Laura ;

Grogan, Tristan ;

Esfandiari, Rouzbeh ;

Allen-Auerbach, Martin ;

Quon, Andrew ;

Bahri, Shadfar ;

Gupta, Pawan ;

Gardner, Linda ;

Ranganathan, David ;

Slavik, Roger ;

Dahlbom, Magnus ;

Herrmann, Ken ;

Delpassand, Ebrahim ;

Fendler, Wolfgang P. ;

Czernin, Johannes .

JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) :1440-1446

[9]

Clarke Noel W, 2022, NEJM Evid, V1, pEVIDoa2200043, DOI 10.1056/EVIDoa2200043

[10] Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer [J].

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wuelfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerdur ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel ;

de Wit, Ronald ;

de Bono, Johann ;

Sternberg, Cora N. ;

Fizazi, Karim ;

Tombal, Bertrand ;

Wulfing, Christian ;

Kramer, Gero ;

Eymard, Jean-Christophe ;

Bamias, Aristotelis ;

Carles, Joan ;

Iacovelli, Roberto ;

Melichar, Bohuslav ;

Sverrisdottir, Asgerour ;

Theodore, Christine ;

Feyerabend, Susan ;

Helissey, Carole ;

Ozatilgan, Ayse ;

Geffriaud-Ricouard, Christine ;

Castellano, Daniel .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (26) :2506-2518

← 1 2 3 →